Skip to content

To evaluate the safety and efficacy of endoscopic laparoscopy combined with fluorescent laparoscopic staging of endometrial cancer (total hysterectomy with double adnexectomy plus sentinel lymphadenectomy/pelvic lymphadenectomy)

To evaluate the safety and efficacy of endoscopic laparoscopy combined with fluorescent laparoscopic staging of endometrial cancer (total hysterectomy with double adnexectomy plus sentinel lymphadenectomy/pelvic lymphadenectomy)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127915
Enrollment
Unknown
Registered
2026-07-09
Start date
2023-09-04
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial cancer

Interventions

Sponsors

Peking Union Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patient was diagnosed with endometrial cancer, and the preoperative imaging examination suggested that the diagnosis was stage I (FIGO 2009 stage); 2. The pathology of curettage was endometrioid carcinoma; 3. Pathology suggests high or moderate differentiation (G1 or G2); 4. Age 18-80 years old (inclusive); 5. Be able to cooperate with and complete follow-up and related examinations; 6. Voluntarily participate in the experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. There is a serious uncontrolled disease or acute infection; 2. Patients with cardiovascular and cerebrovascular diseases, blood system diseases, immune system diseases and diabetes that cannot be controlled and cannot meet the surgical standards; 3. Scrape pathology suggested low differentiation or high grade (G3); 4. The pathology of curettage indicated serous carcinoma, clear cell carcinoma and carcinosarcoma; 5. Preoperative radiotherapy, chemotherapy and other adjuvant treatment; 6. Imaging showed positive pelvic or abdominal paraaortic lymph nodes; 7. Poor vaginal conditions, unable to complete removal of the uterus (assessed by researchers); 8. Patients with serious pelvic and abdominal adhesions who are not suitable for laparoscopic surgery; 9. Participants in other investigational drug or device clinical trials have not been completed.

Design outcomes

Primary

MeasureTime frame
Rate of unconverted surgery;

Secondary

MeasureTime frame
Operation time;Sentinel lymph node resection;Intraoperative bleeding;Intraoperative blood transfusion;Sentinel lymph node imaging success ratio;Location and number of sentinel lymph nodes removed;Postoperative pain score;Incidence of device defects;Surgeon's satisfaction;

Countries

China

Contacts

Public ContactXiang Yang

Peking Union Hospital, Chinese Academy of Medical Sciences

Xiangy@pumch.cn+86 135 1105 0222

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026